SurfWax News Index  |  Track News  |  Save/Exchange Information |  WikiWax |  About Us News and Articles on Lorus Therapeutics (LORFF.OB)   CBS Marketwatch Quote Chart Yahoo! Finance: Profile Key Statistics SEC Filings MSN Money Earnings Estimates Financial Results Insider Trading   Lorus Therapeutics Announces Settlement of Secured Convertible Debentures  Jun 23, 2009 "Agreement with ZOR PharmaceuticalsAs previously announced on April 8, 2008 Lorus entered into an exclusive multinational license agreement with ZOR formed as a subsidiary of Zoticon Bioventures Inc. Under the terms of the agreement, Lorus was entitled to receive payments in excess of U.S.$12 million upon achievement of various milestone events and royalties that vary from 10-20% depending on achieving of sales of Virulizin and subject to certain other adjustments. In addition, Lorus received... (CCNMatthews Press Releases) Lorus Announces Report of Evidence of Clinical Activity in Clinical Trial of LOR-2040 Combined With Capecitabine and Oxaliplatin in the Treatment of Advanced Metastatic Solid Tumors  Apr 15, 2009 Press Release Source: Lorus Therapeutics Inc. ... TORONTO, ONTARIO--(Marketwire - April 15, 2009) - Lorus Therapeutics Inc. (TSX: - ; "Lorus"), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, today announced the publication by study investigators of the results of a clinical trial with its lead drug LOR-2040, formerly known as GTI-2040, in combination with capecitabine and oxaliplatin in patients... (CCNMatthews Press Releases) Lorus Therapeutics Reports Third Quarter Results for Fiscal Year 2009  Apr 14, 2009 Press Release Source: Lorus Therapeutics Inc. ... TORONTO, ONTARIO--(Marketwire - April 13, 2009) - Lorus Therapeutics Inc. (Lorus)(TSX: - ), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, today reported financial results for the three and nine months ended February 28, 2009 ... Lorus Therapeutics Inc. Interim Consolidated Statements of Loss and Deficit (unaudited) Three Three Nine Nine months... (CCNMatthews Press Releases) Back to Company News News [ Terms Of Use | Privacy | About ] ©1998-2006 SurfWax, Inc. All rights reserved. Patents pending. Copyright SurfWax, Inc. 2006